Cystatin C in HIV Patients: More than just a GFR marker ?

Gagneux-Brunon, Amandine; Mariat, Christophe; DELANAYE, Pierre

Request a copy

Contribution to collective works (Parts of books)

Cystatin C in HIV Patients: More than just a GFR marker ?

Gagneux-Brunon, Amandine; Mariat, Christophe; DELANAYE, Pierre

2011 • In Cohen, J. B.; Ryseck, L. P. (Eds.) Cystatins: Protease Inhibitors, Biomarkers and Immunomodulators

Permalink
https://hdl.handle.net/2268/88601

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

cystatin C & HIV-novapublisherbook.doc

Author preprint (173.57 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Urology & nephrology

Author, co-author :

Gagneux-Brunon, Amandine

Mariat, Christophe

DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie

Language :

English

Title :

Cystatin C in HIV Patients: More than just a GFR marker ?

Publication date :

2011

Main work title :

Cystatins: Protease Inhibitors, Biomarkers and Immunomodulators

Editor :

Cohen, J. B.

Ryseck, L. P.

Publisher :

Nova Science Publisher, New York, United States - New York

Available on ORBi :

since 08 April 2011

Statistics

Number of views

52 (1 by ULiège)

Number of downloads

1 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS. 2008;22 Suppl 3:S7-12.
Seaberg EC, Muñoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953-960.
Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes. 2003;52(7):1695-1700.
Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007;8(5):280-287.
Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J. Am. Soc. Nephrol. 2005;16(8):2412-2420.
Fernando SK, Finkelstein FO, Moore BA, Weissman S. Prevalence of chronic kidney disease in an urban HIV infected population. Am. J. Med. Sci. 2008;335(2):89-94.
Crum-Cianflone N, Ganesan A, Teneza-Mora N, et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010;24(6):353-360.
Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J. Infect. Dis. 2008;197(11):1548-1557.
Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mondy KE. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med. 2009;10(6):343-350.
Vupputuri S, Batuman V, Muntner P, et al. The risk for mild kidney function decline associated with illicit drug use among hypertensive men. Am. J. Kidney Dis. 2004;43(4):629-635.
Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667-1678.
Tordato F, Cozzi Lepri A, Cicconi P, et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12(1):4-13.
Estrella MM, Parekh RS, Abraham A, et al. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J. Acquir. Immune Defic. Syndr. 2010;55(2):217-220.
Mayor AM, Dworkin M, Quesada L, Ríos-Olivares E, Hunter-Mellado RF. The morbidity and mortality associated with kidney disease in an HIV-infected cohort in Puerto Rico. Ethn Dis. 2010;20(1 Suppl 1):S1-163-7.
George E, Lucas GM, Nadkarni GN, et al. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24(3):387-394.
Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin. Infect. Dis. 2004;39(8):1199-1206.
de Silva TI, Post FA, Griffin MD, Dockrell DH. HIV-1 infection and the kidney: an evolving challenge in HIV medicine. Mayo Clin. Proc. 2007;82(9):1103-1116.
Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 2005;40(11):1559-1585.
Estrella MM, Fine DM. Screening for chronic kidney disease in HIV-infected patients. Adv Chronic Kidney Dis. 2010;17(1):26-35.
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N. Engl. J. Med. 2006;354(23):2473-2483.
Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin. Chem. 1992;38(10):1933-1953.
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 2002;40(2):221-226.
Séronie-Vivien S, Delanaye P, Piéroni L, et al. Cystatin C: current position and future prospects. Clin. Chem. Lab. Med. 2008;46(12):1664-1686.
Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416-1421.
Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75(6):652-660.
Conti M, Moutereau S, Zater M, et al. Urinary cystatin C as a specific marker of tubular dysfunction. Clin. Chem. Lab. Med. 2006;44(3):288-291.
Herget-Rosenthal S, van Wijk JAE, Bröcker-Preuss M, Bökenkamp A. Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin. Biochem. 2007;40(13-14):946-951.
Röling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin. Infect. Dis. 2006;42(10):1488-1495.
Jaafar A, Séronie-Vivien S, Malard L, et al. Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. AIDS. 2009;23(2):257-259.
Delanaye P, Cavalier E, Maillard N, et al. [Creatinine: past and present]. Ann. Biol. Clin. (Paris). 2010;68(5):531-543.
Visnegarwala F, Shlay JC, Barry V, et al. Effects of HIV infection on body composition changes among men of different racial/ethnic origins. HIV Clin Trials. 2007;8(3):145-154.
Delpierre C, Bonnet E, Marion-Latard F, et al. Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls. J Clin Densitom. 2007;10(4):376-380.
Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 2003;36(Suppl 2):S69-78.
McDermott AY, Terrin N, Wanke C, et al. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin. Infect. Dis. 2005;41(11):1662-1670.
Nahlen BL, Chu SY, Nwanyanwu OC, et al. HIV wasting syndrome in the United States. AIDS. 1993;7(2):183-188.
Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184):1112-1115.
Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit. 1983;5(2):161-168.
Singal A, Anand BS. Management of hepatitis C virus infection in HIV/HCV coinfected patients: clinical review. World J. Gastroenterol. 2009;15(30):3713-3724.
Chun HM, Fieberg AM, Hullsiek KH, et al. Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin. Infect. Dis. 2010;50(3):426-436.
Jones CY, Jones CA, Wilson IB, et al. Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study. Am. J. Kidney Dis. 2008;51(6):914-924.
Fischer MJ, Wyatt CM, Gordon K, et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J. Acquir. Immune Defic. Syndr. 2010;53(2):222-226.
Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch. Intern. Med. 2007;167(20):2213-2219.
Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J. Urol. 1975;114(6):802-808.
Myre SA, McCann J, First MR, Cluxton RJ. Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers. Ther Drug Monit. 1987;9(2):161-165.
Maki DG, Fox BC, Kuntz J, Sollinger HW, Belzer FO. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine. J. Lab. Clin. Med. 1992;119(1):11-24.
Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58(RR-11):1-166.
Neuhaus J, Jacobs DR, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 2010;201(12):1788-1795.
Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, et al. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir. Ther. (Lond.). 2006;11(5):641-645.
Mocroft A, Wyatt C, Szczech L, et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS. 2009;23(1):71-82.
Longenecker CT, Scherzer R, Bacchetti P, et al. HIV viremia and changes in kidney function. AIDS. 2009;23(9):1089-1096.
Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22(4):481-487.
Woitas RP, Stoffel-Wagner B, Flommersfeld S, et al. Correlation of Serum Concentrations of Cystatin C and Creatinine to Inulin Clearance in Liver Cirrhosis. Clin Chem. 2000;46(5):712-715.
Pöge U, Gerhardt T, Stoffel-Wagner B, et al. Calculation of glomerular filtration rate based on Cystatin C in cirrhotic patients. Nephrology Dialysis Transplantation. 2006;21(3):660-664.
Mauss S, Berger F, Kuschak D, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir. Ther. (Lond.). 2008;13(8):1091-1095.
Esezobor CI, Iroha E, Oladipo O, et al. Kidney function of HIV-infected children in Lagos, Nigeria: using Filler's serum cystatin C-based formula. J Int AIDS Soc. 2010;13:17.
Ciborowski P, Kadiu I, Rozek W, et al. Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology. 2007;363(1):198-209.
Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann. Intern. Med. 2006;145(4):237-246.
Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med. 2005;352(20):2049-2060.
Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(2):173-179.
Hoke M, Amighi J, Mlekusch W, et al. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke. 2010;41(4):674-679.
El-Sadr WM, Lundgren JD, NeatonJD, et al. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 2006;355(22):2283-2296.
Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J. Infect. Dis. 2009;200(6):973-983.
Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir. Ther. (Lond.). 2008;13(2):177-187.
Falasca K, Ucciferri C, Mancino P, et al. Cystatin C, adipokines and cardiovascular risk in HIV infected patients. Curr. HIV Res. 2010;8(5):405-410.
Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am. J. Kidney Dis. 2010;56(5):872-882.
Barraclough K, Er L, Ng F, et al. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract. 2009;111(1):c39-48.
Beringer PM, Owens H, Nguyen A, et al. Estimation of glomerular filtration rate by using serum cystatin C and serum creatinine concentrations in patients with human immunodeficiency virus. Pharmacotherapy. 2010;30(10):1004-1010.
Bonjoch A, Bayés B, Riba J, et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral Res. 2010;88(3):347-354.
van Deventer HE, Paiker JE, Katz IJ, George JA. A comparison of cystatin C-and creatinine-based prediction equations for the estimation of glomerular filtration rate in black South Africans. Nephrol Dial Transplant. 2010. doi: 10.1093/ndt/gfq621
Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin. Chim. Acta. 2002;323(1-2):121-128.
Conti M, Moutereau S, Zater M, et al. Urinary cystatin C as a specific marker of tubular dysfunction. Clin. Chem. Lab. Med. 2006;44(3):288-291.
Herget-Rosenthal S, Poppen D, Hüsing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin. Chem. 2004;50(3):552-558.
Nejat M, Pickering JW, Walker RJ, et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care. 2010;14(3):R85.
Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin. Infect. Dis. 2006;42(2):283-290.
Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab. Invest. 2009;89(5):513-519.
Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS. 2005;19(1):93-95.
Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res. Hum. Retroviruses. 2009;25(4):387-394.
Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J. Acquir. Immune Defic. Syndr. 2010;53(1):62-69.
Brim NM, Cu-Uvin S, Hu SL, O'Bell JW. Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read. 2007;17(6):322-328, C3.
Mazuecos A, Fernandez A, Andres A, et al. HIV infection and renal transplantation. Nephrol Dial Transplant. 2010 doi:10.1093/ndt/gfq592
Landin L, Rodriguez-Perez JC, Garcia-Bello MA, et al. Kidney transplants in HIV-positive recipients under HAART. A comprehensive review and meta-analysis of 12 series. Nephrol. Dial. Transplant. 2010;25(9):3106-3115.
Stock PG, Barin B, Murphy B, et al. Outcomes of Kidney Transplantation in HIV-Infected Recipients. N Engl J Med. 2010;363(21):2004-2014.
Choi AI, Rodriguez RA, Bacchetti P, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin. Infect. Dis. 2007;45(12):1633-1639.
Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int. 2010;78(11):1060-1063.
Bonjoch A, Bayés B, Riba J, et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral Res. 2010. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20887753 [Accédé Octobre 17, 2010].